Table 3 Potential biomarkers confirmed using tandem mass spectrometry. List of metabolites that showed significant alterations in early vs late stages of EC. (m/z = mass/charge; ppm = parts per million; RT = retention time; p-v = p-value; FC = fold change; FDR = false discovery rate; AUC = area under the curve).

From: Metabolomic and Lipidomic Profiling Identifies The Role of the RNA Editing Pathway in Endometrial Carcinogenesis

Metabolite

m/z

Mass error (ppm)

RT (min)

Early vs late EC stages

FC (early/late)

p-value

FDR

AUC

Formula

Ionization mode

Column

Major CID fragments

Arachidonic Acid

303.2325

1

6.8246

0.1402

6.24E-03

8.74E-03

0.778

C20H32O2

Negative

C18_BEH

259.25, 216.99, 205.19

PC(16:0/20:5)

780.5545

0

8.8476

0.3311

3.13E-03

5.48E-03

0.750

C44H78NO8P

Positive

C18_BEH

88.11, 184.07, 255.21, 393.24

PC(16:0/22:6)

806.5709

1

9.0460

3.0814

7.86E-04

5.48E-03

0.807

C46H80NO8P

Positive

C18_BEH

184.07, 267.21, 478.32, 550.32, 623.50

PE(16:0/22:6)

762.5106

3

9.0937

2.0349

8.36E-03

9.75E-03

0.752

C43H74NO8P

Negative

C18_BEH

140.01, 255.23, 283.24, 327.23, 452.27

PE(18:1/22:6)

788.5258

2

9.1145

15.2799

2.2E-02

2.20E-02

0.676

C45H76NO8P

Negative

CSH and C18_BEH

78.95 140.01, 152.99, 281.24, 283.26, 327.23, 460.26, 478.29, 506.26

PE(22:6/P-18:1)

772.5278

1

9.3001

0.4065

1.86E-03

5.48E-03

0.800

C45H76NO7P

Negative

CSH and C18_BEH

140.01, 283.24, 327.23, 444.28, 462.29

UDP-N-acetyl-D-galactosamine

606.0739

0

0.5454

0.3765

2.97E-02

5.48E-03

0.688

C17H27N3O17P2

Negative

C18_BEH

111.0222, 158.92, 176.93, 282.04, 362.00, 385.00